Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis
Siskind, Dan, Hahn, Margaret, Correll, Christoph U., Fink‐Jensen, Anders, Russell, Anthony W., Bak, Nikolaj, Broberg, Brian V., Larsen, Julie, Ishøy, Pelle L., Vilsbøll, Tina, Knop, Filip K., Kisely, Steve, Ebdrup, Bjørn H.
Published in Diabetes, obesity & metabolism (01.02.2019)
Published in Diabetes, obesity & metabolism (01.02.2019)
Get full text
Journal Article
Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial
Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjørn H.
Published in Diabetes, obesity & metabolism (01.02.2017)
Published in Diabetes, obesity & metabolism (01.02.2017)
Get full text
Journal Article
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Eriksson, Robert, Broberg, Brian V, Ishøy, Pelle L, Bak, Nikolaj, Andersen, Ulrik B, Jørgensen, Niklas R, Knop, Filip K, Ebdrup, Bjørn H
Published in Frontiers in psychiatry (28.01.2019)
Published in Frontiers in psychiatry (28.01.2019)
Get full text
Journal Article
Erratum: Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial
Ebdrup, Bjørn H., Broberg, Brian V., Ishøy, Pelle L., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Knop, Filip K., Glenthøj, Birte Y.
Published in Diabetes, obesity & metabolism (01.05.2018)
Published in Diabetes, obesity & metabolism (01.05.2018)
Get full text
Journal Article
Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
Ishøy, Pelle L., Knop, Filip K., Vilsbøll, Tina, Glenthøj, Birte Y., Ebdrup, Bjørn H.
Published in The American journal of psychiatry (01.06.2013)
Published in The American journal of psychiatry (01.06.2013)
Get full text
Journal Article
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
Ishøy, Pelle L, Knop, Filip K, Broberg, Brian V, Baandrup, Lone, Fagerlund, Birgitte, Jørgensen, Niklas R, Andersen, Ulrik B, Rostrup, Egill, Glenthøj, Birte Y, Ebdrup, Bjørn H
Published in BMJ open (01.01.2014)
Published in BMJ open (01.01.2014)
Get full text
Journal Article
Poster #218 GLUCAGON-LIKE PEPTIDE-1 ANALOGUES AGAINST ANTIPSYCHOTIC-INDUCED OVERWEIGHT: POTENTIAL PHYSIOLOGICAL BENEFITS
Ebdrup, Björn H, Knop, Filip K, Ishoy, Pelle L, Rostrup, Egill, Fagerlund, Birgitte, Lublin, Henrik, Glenthøj, Birte
Published in Schizophrenia research (01.04.2012)
Published in Schizophrenia research (01.04.2012)
Get full text
Journal Article
SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity
Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Fagerlund, Birgitte, Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjorn
Published in Schizophrenia bulletin (01.03.2017)
Published in Schizophrenia bulletin (01.03.2017)
Get full text
Journal Article
Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes
Ishøy, Pelle L, Knop, Filip K, Vilsbøll, Tina, Glenthøj, Birte Y, Ebdrup, Bjørn H
Published in The American journal of psychiatry (01.06.2013)
Published in The American journal of psychiatry (01.06.2013)
Get full text
Report